AMERSFOORT, The Netherlands--(BUSINESS WIRE)--Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, announced today that it has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge™ biomaterial in accordance with the international ISO 10993 standards. Regulatory agencies such as the European Council or the U.S. Food and Drug Administration (FDA) rely on the ISO standards to ensure the safety of biocompatible materials before clinical trials are initiated. Completion of the ISO 10993 is an essential step in bringing FlexiSurge’s commercial development forward.